Quince Therapeutics Appoints Dr. Charles S. Ryan as President
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.
- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President.
- Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “Charles is a valuable addition to our management team.
- His considerable expertise will help enhance efficiency and effectiveness across our research programs and business operations.
- Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions.